New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 3, 2013
06:42 EDTREGN, SNYRegeneron acquires full rights to two novel development programs from Sanofi
Regeneron Pharmaceuticals (REGN) announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi (SNY). Regeneron acquired full rights to antibodies targeting the PDGF, or platelet derived growth factor, family of receptors and ligands in ophthalmology and all other indications and to antibodies targeting the ANG2 receptor and ligand in ophthalmology. Antibodies to PDGF and ANG2 are currently in preclinical development for use in ophthalmology. With respect to PDGF antibodies, Regeneron will pay Sanofi $10M upfront, up to $40M in development milestone payments, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi $10M upfront, a potential $5M development milestone payment, and royalties on sales.
News For REGN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
06:19 EDTSNYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
06:43 EDTREGNRegeneron price target raised to $527 from $445 at Leerink
Subscribe for More Information
April 22, 2015
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded on post-merger outlook at Bernstein... Amazon.com (AMZN) upgraded to Buy, price target raised to $450 at Monness Crespi... BNP Paribas (BNPQY) upgraded to Overweight from Equal Weight at Morgan Stanley... Dolby (DLB) upgraded to Overweight from Neutral at JPMorgan... First Defiance (FDEF) upgraded to Outperform from Market Perform at Raymond James... Gran Tierra (GTE) upgraded to Buy from Neutral at Dundee... Grupo Aval (AVAL) upgraded to Buy from Neutral at Goldman... Manhattan Associates (MANH) upgraded to Buy from Hold at Benchmark Co.... Marriott (MAR) upgraded to Buy from Neutral at MKM Partners... Masco (MAS) upgraded to Outperform from Market Perform at FBR Capital... Nokia (NOK) upgraded on post-merger outlook at Bernstein... Packaging Corp. (PKG) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Sector Perform from Underperform at RBC Capital... Rogers Communications (RCI) upgraded to Buy from Neutral at BofA/Merrill... Sanofi (SNY) upgraded to Neutral from Sell at Citigroup... Select Comfort (SCSS) upgraded to Outperform from Neutral at Wedbush... UniCredit (UNCFF) upgraded to Buy from Sell at Berenberg... Zions Bancorp (ZION) upgraded to Outperform from Market Perform at FBR Capital.
07:07 EDTSNYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
06:52 EDTSNYSanofi upgraded to Neutral from Sell at Citigroup
Subscribe for More Information
April 21, 2015
09:01 EDTSNYGenzyme initiates Phase 2a trial to evaluate pharmocodynamics of GZ/SAR402671
Subscribe for More Information
April 20, 2015
09:20 EDTSNY, REGNLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
April 15, 2015
11:56 EDTSNYSanofi initiated with a Buy at Societe Generale
Subscribe for More Information
07:41 EDTSNYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use